Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 4,023 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Duchenne Muscular Dystrophy
Interventions: INS1201; Genetic
Lead sponsor: Insmed Gene Therapy LLC; Industry
Eligibility: 2 Years to 4 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Little Rock, Arkansas • Davis, California • Los Angeles, California + 7 more

Conditions: Ventilator Associated Pneumonia, Bronchopulmonary Dysplasia, Respiratory Disease
Interventions: Standardized oral Care; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 1 Hour to 3 Days
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: HIV
Interventions: PRO 140 (350 mg), PRO 140 (525 mg), PRO 140 (700 mg); Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 562 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 12
States / cities: La Mesa, California • Palm Springs, California • San Francisco, California + 9 more

Conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: trastuzumab, gefitinib, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Renal Cell Carcinoma
Interventions: Atezolizumab, Bevacizumab, RO6874281; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: New Haven, Connecticut • Chicago, Illinois • Baltimore, Maryland

Conditions: Solid Tumours
Interventions: GSK1363089; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Detroit, Michigan • Houston, Texas

Conditions: Triple Negative Breast Cancer, Metastatic Breast Cancer
Interventions: Pembrolizumab, PVX-410; Drug · Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Recurrent Glioblastoma Multiforme(GBM)
Interventions: ACT001, ACT001 + Pembrolizumab; Drug
Lead sponsor: Accendatech USA Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
Interventions: Tagraxofusp, Fludarabine, Cytarabine, Dexamethasone, Vincristine, Azacitidine, Methotrexate, Cytarabine IT, Hydrocortisone; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Year to 21 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 29
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 25 more

Conditions: Neurofibromatosis 1, Plexiform Neurofibroma
Interventions: Selumetinib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Year to 8 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 11 more

Conditions: Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer
Interventions: Lenvatinib, ABBV-324; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 10
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 7 more

Conditions: Actinic Keratosis
Interventions: Ingenol mebutate gel, placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Carmel, Indiana

Conditions: Prevention
Interventions: Integrated Behavioral Health - Prevention, Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4th Edition; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Radiation Injury, Breast Cancer
Interventions: Proton beam radiation therapy., X-ray based radiation therapy, Computed Tomography (CT) Scan, Pulmonary Function Test (PFT); Radiation · Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Classical Hodgkin Lymphoma
Interventions: Pembrolizumab, Doxorubicin, Vinblastine, Dacarbazine, Bleomycin, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisone; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Fullerton, California • Palo Alto, California • Chicago, Illinois + 3 more

Conditions: Hiv, Fatigue, Mobility Limitation
Interventions: HIIT (intervention), CME (active control), Coaching, Control text message; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Aurora, Colorado • Seattle, Washington

Conditions: Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
Interventions: Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), gemcitabine/nab-paclitaxel, Capecitabine, Pazopanib, Pembrolizumab, Paclitaxel, nivolumab, Gemcitabine/carboplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 7 more

Conditions: Multiple Myeloma
Interventions: Selinexor, Dexamethasone; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 36
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 28 more

Conditions: Clinical High Risk for Psychosis (CHR)
Interventions: CBT Skills Group for CHR Youth, Individual CBT sessions, CBT Skills Group for Families; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 14 Years to 25 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma
Interventions: GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D); Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Autism Spectrum Disorder, Obesity
Interventions: Glucagon-like peptide-1 receptor agonist：Semaglutide, Lifestyle Management (LSM) Counseling; Drug · Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Relapsed Acute Myeloid Leukemia
Interventions: Imetelstat, Azacitidine, Venetoclax; Drug
Lead sponsor: Douglas Tremblay; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: New York, New York

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: CB-011; Biological
Lead sponsor: Caribou Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 16
States / cities: Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 12 more

Conditions: Cardiovascular Health
Interventions: Physical activity coaching; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)

Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit

Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection

Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer

Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)

A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors

PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis

Integrated Behavioral Health Prevention in Pediatric Primary Care for Infants

Breast Cancer Lung Late Effects

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

High-Intensity Exercise to Attenuate Limitations and Train Habits in Older Adults With HIV

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Selinexor Treatment of Refractory Myeloma

Telehealth Cognitive Behavioral Therapy for Youth at Risk for Psychosis

Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity

Semaglutide in Youth With Autism Spectrum Disorder

Imetelstat Combinations in Relapsed AML

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

MyHeart Counts: Stanford Mobile Cardiovascular Health Study 3.0